retatrutide type 2 diabetes phase 2 trial results 2024 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide study sees significant weight

Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients

The gut microbiome in hyperuricemia and gout

That is the entire workaround

GLP1s help with hunger

Clment K et al

"In addition, these results highlight the need for further research to elucidate potential mechanistic links between GLP-1 receptor agonist therapy, weight loss, and hair loss, and to identify patient level risk factors that may increase susceptibility to hair loss." It's worth pointing out that the medical records the researchers were dealing with were limited in terms of measuring the severity and duration of the hair loss, and whether or not it was reversible